War on C Difficile Is Being Fought On Multiple Fronts
Pivotal trials are underway for two microbiota restoration therapies, a narrow-spectrum antibiotic and a vaccine; funding from non-profits and new owners have revived stalled projects at Summit, Deinove and MGB Biopharma.
You may also be interested in...
Company’s Phase III program is attempting to replicate Phase II efficacy data showing superiority for curing Clostridium difficile infections and preventing recurrence, while also compiling health economics data.
Thomas Lingelbach talks to Scrip about Valneva’s plans for a US IPO to fund Phase III studies of its lead Lyme disease vaccine.
The Swiss group is expanding its alliance with the Karolinska Institutet to conduct 10 studies designed to improve understanding of the microbiome’s impact on reproductive and gut health challenges.